Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services tags : Alzheimer save search
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
Published: 2022-03-15 (Crawled : 13:30) - biospace.com/
GANX | $3.155 0.16% 0.16% 71K
|
Professional, Scientific, and T...
|
| O: 9.7%
H: 2.76%
C: -7.46%
alzheimer pos parkinson conference therapeutics disease positive alzheimer’s alzheimer's disease alzheimer's
Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)
Published: 2022-03-15 (Crawled : 13:30) - prnewswire.com
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 7.12%
C: -2.15%
alzheimer parkinson research conference disease potential international tiona alzheimer’s bryostatin alzheimer's
Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients
Published: 2022-02-01 (Crawled : 15:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 5.13%
H: 29.88%
C: 23.05%
alzheimer disease alzheimer’s alzheimer's disease bryostatin alzheimer's
Alzamend Neuro Announces Positive Topline Data from Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al001 alzheimer treatment dementia trial phase 1 positive topline alzheimer’s alzheimer's
Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al001 alzheimer dementia liver trial phase 1 topline alzheimer’s alzheimer's
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients’ Immunological System to Combat Alzheimer’s Disease
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al002 alzheimer fda system disease cel positive pons vaccine alzheimer’s alzheimer's disease alzheimer's
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al001 alzheimer dementia trial disease alzheimer’s alzheimer's disease alzheimer's
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
Published: 2022-01-12 (Crawled : 20:00) - alzamend.com
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 0.54%
H: 7.03%
C: -0.54%
al001 alzheimer dementia contract disease alzheimer’s alzheimer's disease alzheimer's
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
Published: 2021-12-06 (Crawled : 14:00) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 1.23%
H: 0.0%
C: 0.0%
alzheimer treatment fda phase 2 clearance therapeutics disease alzheimer’s alzheimer's disease alzheimer's
Cyclo Therapeutics Submits Investigational New Drug Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease
Published: 2021-11-16 (Crawled : 13:30) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 4.33%
H: 7.65%
C: -4.8%
new drug disease alzheimer treatment fda phase 2 application drug alzheimer’s alzheimer's disease alzheimer's
Cyclo Therapeutics Names Preeminent Neuroscientist and World-Renowned Researcher, Cynthia A. Lemere, PhD, as Senior Advisor for Advancement of Alzheimer’s Disease Asset
Published: 2021-11-02 (Crawled : 13:00) - biospace.com/
CYTH | $1.19 -0.83% -0.84% 57K
|
Professional, Scientific, and T...
|
| O: 1.0%
H: 8.37%
C: 8.37%
disease alzheimer research alzheimer’s alzheimer's disease alzheimer's
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Published: 2021-11-02 (Crawled : 12:00) - globenewswire.com
ABOS | $3.14 -0.63% -0.64% 310K
|
Professional, Scientific, and T...
|
| O: -4.4%
H: 8.83%
C: -1.17%
disease alzheimer clinical trials phase 1 trials trial conference alzheimer’s alzheimer's disease alzheimer's designation
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
Published: 2021-10-07 (Crawled : 13:00) - biospace.com/
ABOS | $3.14 -0.63% -0.64% 310K
|
Professional, Scientific, and T...
|
| O: 0.81%
H: 0.0%
C: -1.14%
disease alzheimer treatment phase 1 antibody trial aβos alzheimer’s alzheimer's disease alzheimer's
Alzamend Neuro Announces It Has Contracted With Altasciences to Conduct a Phase I Relative Bioavailability Study for AL001 for Dementia Related to Alzheimer’s Disease in September 2021
Published: 2021-08-17 (Crawled : 13:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -2.57%
H: 1.46%
C: -3.23%
disease alzheimer dementia contract al001 alzheimer’s alzheimer's disease alzheimer's
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending
Published: 2021-08-04 (Crawled : 12:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 3.49%
H: 2.02%
C: -2.25%
new drug alzheimer dementia drug al001 alzheimer’s alzheimer's
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient’s Immunological System to Combat Alzheimer’s
Published: 2021-07-30 (Crawled : 11:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: 0.0%
alzheimer al002 vaccine submission cel alzheimer’s alzheimer's
Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021
Published: 2021-07-26 (Crawled : 14:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 3.72%
H: 1.59%
C: -21.99%
presentation alzheimer positive results positive results trial conference alzheimer’s bryostatin alzheimer's
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease
Published: 2021-07-23 (Crawled : 11:00) - biospace.com/
ALZN | $0.6894 -0.23% -0.23% 28K
|
Professional, Scientific, and T...
|
| O: 41.81%
H: 1.72%
C: -29.61%
disease alzheimer al002 positive results positive results alzheimer’s alzheimer's disease alzheimer's
Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline
Published: 2021-07-14 (Crawled : 14:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 9.88%
C: 9.74%
alzheimer conference alzheimer’s bryostatin alzheimer's
Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease
Published: 2021-07-07 (Crawled : 14:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 1.01%
C: -14.65%
disease alzheimer patent alzheimer’s alzheimer's disease alzheimer's awards
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.